All Journal articles – Page 5
-
JournalUsing data to drive regulatory performance
Life sciences companies, whether they are pharma, biotech, MedTech or diagnostic, all aim to get products to patients as quickly and efficiently as possible. To do so, they rely on knowledge of their regulatory ecosystem (henceforth referred to as regulatory intelligence).
-
JournalOrganising high quality research and development data for success
Regulatory functions have long discussed the quality of the data in regulatory information management (RIM) systems, and various data entry models have waxed and waned over the years. According to current research, there is no correlation between the data entry model and the quality of the data in RIM systems. However, this article argues that managing data in research and development (R&D) silos is the key reason for variable data quality across the R&D data value chain, and that a change in how R&D operations functions are organised could be the secret to success.
-
JournalAn industry perspective on the use of patient experience data in medicines development: Is further action needed from European regulators?
Engaging with patients to understand their experiences, needs and preferences provides important information to sponsors of medicines development as well as to decision-makers, and integrating this information into every stage of medical product development can significantly enhance the therapeutic landscape for all stakeholders.
-
JournalImmunological considerations in the development of novel vaccines
This article explores the critical elements of the immune response that contribute to vaccine effectiveness, with reference to the European Medicines Agency’s (EMA) recent scientific guideline on clinical evaluation of new vaccines.
-
JournalRegulatory strategy implications for foetal medicine
Regulation (EC) 1901/2006 is clear that paediatric investigation plans (PIPs) apply to children from birth to 18 years of age, which omits the unborn foetus. To understand whether any recommendations exist which would support seeking agreement on a PIP for this special population, a review of European legislation, guidelines and other application precedents was undertaken. This article summarises the review and provides insight into distinctions that may be made by the agency in this matter, as well as highlighting relevant precedents which were identified during the review.
-
JournalImplications of the EU’s AI Act for medical devices and in vitro diagnostic medical devices
The integration of artificial intelligence within healthcare has heralded a new era of innovation for medical devices and in vitro diagnostics. This article explores some implications of the EU’s AI Act for the existing regulatory frameworks governing MDs, specifically the Medical Devices Regulation (EU) 2017/745 and the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746.
-
JournalAn introduction to the Medical Device Single Audit Program
The Medical Device Single Audit Program (MDSAP) is an International Medical Device Regulatory Forum (IMDRF) scheme whereby the regulatory authorities of member jurisdictions have agreed to subcontract regulatory surveillance of the industry to existing notified bodies (NBs).
-
JournalThe EU Medical Device Regulation: Balancing innovation with regulation
The EU Medical Device Regulation (EU MDR) 2017/745 was introduced in response to the need for tighter regulation of medical devices (MDs) in Europe. However, with the increased regulatory burden, there could be potentially hundreds of unanticipated ramifications, particularly for smaller manufacturers and start-ups. By increasing regulation so significantly in a relatively short time period, the very rules which are designed to protect patients may prevent them from accessing the treatment they need and stifle innovation, as start-ups inevitably struggle under the weight of new requirements. This article assesses the delicate balance between innovation and regulation and analyses the relationship between the two.
-
JournalThe role of artificial intelligence in regulatory affairs
This article explores the enormous potential of artificial intelligence (AI) technologies in regulatory affairs, highlighting how AI can streamline regulatory compliance, expedite submissions, enhance predictive analytics for decision-making, improve pharmacovigilance and elevate regulatory intelligence when properly applied. The discussion covers not only the advantages of AI but also the complexities of integrating AI into regulatory affairs, such as the challenges of algorithm interpretability, data quality, regulatory compliance, fairness, security, privacy and model accuracy. Additionally, it emphasises the collaborative efforts of the global regulatory community in developing guidelines and frameworks for the safe and effective use of AI.
-
JournalOverview of chemical generics registration in China: Challenges for overseas applicants
This is the fifth article in a six-part series that focuses on the regulations in China’s drug market. There will be different topics each month with the initial focus on the drug master file (DMF) filing process followed by the drug registration process and pharmacovigilance requirements.
-
JournalAddressing the challenges of implementing the common technical document in Brazil
The common technical document (CTD) is the standard format for regulatory dossiers. It was developed in early 2000 for use in Europe, the United States (US) and Japan, and is currently accepted in several other regions such as Australia, Canada, India, South Africa, Switzerland and, since August 2019, Brazil, with the publication of Guide N°24/2019 from the Brazilian Health Regulatory Agency (Anvisa).
-
JournalConsiderations in the development of allogenic and autologous cell therapies
Autologous cell therapy involves the use of a patient’s own cells which are harvested, modified or expanded ex vivo and then reintroduced into the patient. Allogeneic therapies use cells from a donor modified or expanded ex vivo and then administered to the patient.
-
JournalUnique aspects of biologic reference standards
Reference standards are pivotal in ensuring pharmaceutical quality, especially for complex biologics. This article reviews definitions and classifications of reference standards as outlined by the US Food and Drug Administration (FDA), the World Health Organization (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q6B and Q7 guidelines. It addresses types of standards based on source and use, with particular emphasis on the distinct requirements for biologics.
-
JournalConsiderations for generics developers moving into the field of biosimilars
Many generic developers have experience in both manufacturing and gaining US and EU approval for generics which are small molecule alternatives to the authorised original products. These developers possess the relevant skillsets to allow them to pursue the development of biosimilars, which are large molecule biologics highly similar to the authorised original products.
-
-
-
-
-
-
